FDA To Hold Listening Sessions On Potentially Big Ad Comm Changes

FDA plans to hold a listening session in June to discuss possible changes to the role of its advisory committees, coming as senior agency officials seek to shift the advisers’ focus on product approval decisions to debates surrounding scientific policies. But that push has also faced backlash from some lower-level FDA officials. Specially, FDA announced Monday (April 29) it wants feedback on how it can “clarify any misconception that advisory committee votes are binding on the agency's final decision rather...